ProCE Banner Activity

Practical Insights on Key Data From ESMO 2020 Informing Precision Medicine in NSCLC

Podcast Episodes
In this pocast episode, listen to Helena A. Yu, MD, a medical oncologist, and Maria E. Arcila, MD, a molecular pathologist, discuss new data on actionable mutations and targeted therapies in NSCLC from ESMO 2020, including emerging therapeutic strategies targeting EGFR or KRAS G12C driver mutations.

Released: December 21, 2020

Share

Faculty

Maria E. Arcila

Maria E. Arcila, MD

Associate Attending, Pathology
Diagnostic Molecular Service
Pathology Department
Directory, Diagnostic Molecular Pathology Laboratory
Director, Molecular Hematopathology
Diagnostic Molecular Pathology and Hematopathology
Memorial Sloan Kettering Cancer Center
New York, New York

Helena Yu

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Faculty Disclosure

Primary Author

Maria E. Arcila, MD

Associate Attending, Pathology
Diagnostic Molecular Service
Pathology Department
Directory, Diagnostic Molecular Pathology Laboratory
Director, Molecular Hematopathology
Diagnostic Molecular Pathology and Hematopathology
Memorial Sloan Kettering Cancer Center
New York, New York

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York